Insmed (INSM) Projected to Post Quarterly Earnings on Thursday

Insmed (NASDAQ:INSM) is expected to post its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Insmed to announce earnings of ($0.3879) per share and revenue of $499.06 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.61. The firm had revenue of $425.49 million for the quarter, compared to analyst estimates of $395.50 million. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%. The company’s revenue for the quarter was up 296.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.70) EPS. On average, analysts expect Insmed to post ($1.60) EPS for the current fiscal year and $0.93 EPS for the next fiscal year.

Insmed Stock Performance

INSM stock opened at $93.33 on Tuesday. Insmed has a fifty-two week low of $90.39 and a fifty-two week high of $212.75. The company has a current ratio of 3.72, a quick ratio of 3.40 and a debt-to-equity ratio of 0.74. The business’s fifty day moving average price is $114.59 and its two-hundred day moving average price is $127.06.

Insider Activity at Insmed

In other news, Director David R. Brennan sold 25,000 shares of the stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total value of $3,100,000.00. Following the completion of the transaction, the director owned 39,238 shares of the company’s stock, valued at approximately $4,865,512. This represents a 38.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Roger Adsett sold 239,850 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the completion of the sale, the chief operating officer owned 98,744 shares in the company, valued at approximately $13,159,612.88. The trade was a 70.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 2.10% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts recently commented on INSM shares. Raymond James Financial set a $173.00 price target on shares of Insmed in a research note on Tuesday, October 20th. Roth Capital reaffirmed a “buy” rating and set a $198.00 price target (down from $212.00) on shares of Insmed in a research report on Tuesday, September 15th. Bank of America reiterated a “buy” rating and issued a $207.00 price objective on shares of Insmed in a research note on Monday, October 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a research note on Thursday, October 15th. Finally, Morgan Stanley cut their price objective on shares of Insmed from $218.00 to $213.00 and set an “overweight” rating for the company in a report on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Insmed currently has an average rating of “Moderate Buy” and an average price target of $198.91.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company concentrates on conditions with significant unmet medical needs, particularly in pulmonary and infectious diseases.

Insmed’s lead commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy used in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.